Industry leaders on Health Technology Assessment came together for this round table discussion on the future of HTA in APAC, what lessons can be learned from Europe, and how Asia can blaze it's own trails. IMS Health's Jonathan Tierce, GM of Health Economics and Outcomes Research practice, moderates a discussion with Mandy Chui of IMS Health, Dr. Annie Chicoye of ESSEC Santé Business School France-Singapore, and Dr. Abdulkadir Keskinasian, Market Pricing Director for Novartis in APAC.
Presentación sobre el existencialismo de Sartre enfocada a la materia de Historia de la Filosofía en Bachillerato, realizada por Ana Rosa Moya Escobar.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
The document discusses the history and context around why the United States does not have universal healthcare. It traces the evolution of the healthcare system from the early 1900s through various reforms. While many argue universal healthcare could help prevent deaths and bankruptcy, others believe it would burden taxpayers as it is not free. Historically, the US healthcare system has undergone shifts between private and public involvement through reforms. Legislatively, the checks and balances system and power of private sectors have made it difficult for universal healthcare legislation to pass due to concerns over costs and government control of the economy.
1) The introduction of smartphones in China has propelled its healthcare industry into new areas, but mHealth has not yet dominated due to issues like unmet doctor needs, poor medical coverage, and lack of trust in reliability.
2) A successful example is Sanofi's diabetes mHealth program providing rural residents access to medical experts, and helping companies understand patient needs.
3) Customizing doctor information on platforms like "Ding Xiang Yuan" and "Chunyu Yisheng" allows companies to deliver individualized options to gain insight into doctor needs in the market.
- The document compares the personalities and business strategies of the CEOs of Merck KGaA and Merck & Co.
- Merck KGaA's CEO Karl-Ludwig Kley emphasizes profit maximization and acquisitions to sustain long-term growth, while Merck & Co.'s CEO Kenneth Frazier prioritizes research and development to bring new medicines to patients.
- Despite differing approaches, both companies are now investing heavily in biopharmaceuticals to benefit healthcare systems and patients worldwide.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
Presentación sobre el existencialismo de Sartre enfocada a la materia de Historia de la Filosofía en Bachillerato, realizada por Ana Rosa Moya Escobar.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
The document discusses the history and context around why the United States does not have universal healthcare. It traces the evolution of the healthcare system from the early 1900s through various reforms. While many argue universal healthcare could help prevent deaths and bankruptcy, others believe it would burden taxpayers as it is not free. Historically, the US healthcare system has undergone shifts between private and public involvement through reforms. Legislatively, the checks and balances system and power of private sectors have made it difficult for universal healthcare legislation to pass due to concerns over costs and government control of the economy.
1) The introduction of smartphones in China has propelled its healthcare industry into new areas, but mHealth has not yet dominated due to issues like unmet doctor needs, poor medical coverage, and lack of trust in reliability.
2) A successful example is Sanofi's diabetes mHealth program providing rural residents access to medical experts, and helping companies understand patient needs.
3) Customizing doctor information on platforms like "Ding Xiang Yuan" and "Chunyu Yisheng" allows companies to deliver individualized options to gain insight into doctor needs in the market.
- The document compares the personalities and business strategies of the CEOs of Merck KGaA and Merck & Co.
- Merck KGaA's CEO Karl-Ludwig Kley emphasizes profit maximization and acquisitions to sustain long-term growth, while Merck & Co.'s CEO Kenneth Frazier prioritizes research and development to bring new medicines to patients.
- Despite differing approaches, both companies are now investing heavily in biopharmaceuticals to benefit healthcare systems and patients worldwide.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
1. The document discusses opportunities for France and China to collaborate on improving China's healthcare system to address the country's changing demographic and economic landscape.
2. It outlines four priority areas: developing more patient-centric hospitals and health information systems, caring for an aging population, preventing and managing chronic diseases, and fighting infectious diseases.
3. France is well-positioned to offer relevant experiences and innovative solutions in these areas through its healthcare expertise, long-standing relationship with China, and companies working in areas like hospital design, elderly care, disease prevention and treatment.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
The document provides insights into OTC market trends in the APAC region. It finds that growth in APAC comes from both innovation in new products and base sales growth, while the global market still relies heavily on price increases. Among key categories in APAC, pain relief is driving growth above the regional average, while categories like cough/cold struggle. The report also notes that just 4 of the top 10 OTC corporations in APAC are multinational companies, and only Takeda grows faster than the overall APAC market.
This document summarizes key trends in real-world evidence (RWE) research, with a focus on diabetes. It discusses how new mixed methods and analytic innovations are providing deeper insights into differential treatment responses in diabetes patient subgroups. It also describes emerging RWE strategies like disease-centric frameworks and increased commercial collaboration. Finally, it highlights advances in predictive modeling, leveraging Scandinavian data sources, and using RWE to evaluate disease burden and non-adherence impacts.
The insights driving superior healthcare
outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region to engage in conversations about the forces that are shaping healthcare in Asia - and the strategies necessary to surge ahead of the competition
Growing Pains. China new's realities and the necessity of an informed strateg...QuintilesIMS Asia Pacific
China is a rapidly evolving healthcare market. However companies that take too macroscopic approach to projecting growth, disregarding the more granular trends across drug categories, risk facing a gap between assumed and actual portfolio growth. To address this gap, companies have a variety of options, ranging across levels of difficulty and the degree of transformation necessary.
Download the paper to learn more.
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Understand more about the Awareness, Affordability and Access strategic framework to drive success for global pharma companies engaging with Asian Markets.
While progress has been made in India over the past decade from both public and private sector initiatives, significant challenges persist in providing quality healthcare on an equitable, accessible and affordable basis across all regions and communities, according to a new IMS Institute for Healthcare Informatics study. A 40-45 percent reduction in out-of-pocket expenditures for both outpatient and inpatient treatments can be attained through a holistic approach addressing four critical, interrelated dimensions of healthcare access. Those components are: physical accessibility and the location of healthcare facilities; availability and capacity of needed resources; quality and functionality of service required for patient treatment; and affordability of treatment relative to a patient’s income.
The study – Understanding Healthcare Access in India: What is the Current State? – is the most comprehensive assessment of healthcare access undertaken since 2004 and is based on an extensive survey of nearly 15,000 households covering all socio-economic groups in rural and urban areas across 12 states. Information was gathered on more than 30,000 healthcare system interactions, supplemented by interviews with over 1,000 doctors and experts.
The full report is available at http://www.theimsinstitute.org for downloading.
This presentation wil provide you the latest trends (up to March 2013) on both Global and Asia Pacific OTC markets.
This presentation is in English and Mandarine.
This document provides a global perspective on the evolving biosimilars landscape and market. It finds that after slow initial growth, the biosimilars market is poised for accelerated expansion between 2015-2020 as major biologics lose patent protection, US legislation establishes a regulatory pathway, and payers increase adoption to control costs. The market could reach $1.9-2.6 billion by 2015, up from $378 million currently, with the largest opportunities in oncology, diabetes, and rheumatoid arthritis. Key drivers include cost pressures on healthcare systems and the availability of lower-cost biosimilar alternatives to expensive biologic drugs. However, significant barriers remain due to varying regulations worldwide and resistance from biologics manufacturers.
The document summarizes the changing landscape of the top 10 pharmaceutical companies from 2002 to 2012. It notes that while the companies have remained largely the same, there has been some shuffling between positions. It also discusses how the companies have diversified their business models through mergers and acquisitions, but this has failed to increase their collective market share. The rise of Teva into the top 10 reflects a greater emphasis on generics. Overall, the top companies face challenges in innovating new blockbuster drugs and achieving growth.
The top 20 multinational pharmaceutical companies in Asia will see an average of $950 million in sales become at risk in the next 5 years due to the loss of exclusivity of their top brands. How can MNCs survive and thrive in this increasingly genericized era?
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
A joint effort undertaken by IMS Consulting Group and the Organization of Pharmaceutical Producers of India (OPPI), this white paper offers a glimpse into the findings of a survey with key management personnel in India’s pharmaceutical market about Sales Force structures within the context of changing sales models in the Indian pharma industry.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
1. The document discusses opportunities for France and China to collaborate on improving China's healthcare system to address the country's changing demographic and economic landscape.
2. It outlines four priority areas: developing more patient-centric hospitals and health information systems, caring for an aging population, preventing and managing chronic diseases, and fighting infectious diseases.
3. France is well-positioned to offer relevant experiences and innovative solutions in these areas through its healthcare expertise, long-standing relationship with China, and companies working in areas like hospital design, elderly care, disease prevention and treatment.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
The document provides insights into OTC market trends in the APAC region. It finds that growth in APAC comes from both innovation in new products and base sales growth, while the global market still relies heavily on price increases. Among key categories in APAC, pain relief is driving growth above the regional average, while categories like cough/cold struggle. The report also notes that just 4 of the top 10 OTC corporations in APAC are multinational companies, and only Takeda grows faster than the overall APAC market.
This document summarizes key trends in real-world evidence (RWE) research, with a focus on diabetes. It discusses how new mixed methods and analytic innovations are providing deeper insights into differential treatment responses in diabetes patient subgroups. It also describes emerging RWE strategies like disease-centric frameworks and increased commercial collaboration. Finally, it highlights advances in predictive modeling, leveraging Scandinavian data sources, and using RWE to evaluate disease burden and non-adherence impacts.
The insights driving superior healthcare
outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region to engage in conversations about the forces that are shaping healthcare in Asia - and the strategies necessary to surge ahead of the competition
Growing Pains. China new's realities and the necessity of an informed strateg...QuintilesIMS Asia Pacific
China is a rapidly evolving healthcare market. However companies that take too macroscopic approach to projecting growth, disregarding the more granular trends across drug categories, risk facing a gap between assumed and actual portfolio growth. To address this gap, companies have a variety of options, ranging across levels of difficulty and the degree of transformation necessary.
Download the paper to learn more.
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Understand more about the Awareness, Affordability and Access strategic framework to drive success for global pharma companies engaging with Asian Markets.
While progress has been made in India over the past decade from both public and private sector initiatives, significant challenges persist in providing quality healthcare on an equitable, accessible and affordable basis across all regions and communities, according to a new IMS Institute for Healthcare Informatics study. A 40-45 percent reduction in out-of-pocket expenditures for both outpatient and inpatient treatments can be attained through a holistic approach addressing four critical, interrelated dimensions of healthcare access. Those components are: physical accessibility and the location of healthcare facilities; availability and capacity of needed resources; quality and functionality of service required for patient treatment; and affordability of treatment relative to a patient’s income.
The study – Understanding Healthcare Access in India: What is the Current State? – is the most comprehensive assessment of healthcare access undertaken since 2004 and is based on an extensive survey of nearly 15,000 households covering all socio-economic groups in rural and urban areas across 12 states. Information was gathered on more than 30,000 healthcare system interactions, supplemented by interviews with over 1,000 doctors and experts.
The full report is available at http://www.theimsinstitute.org for downloading.
This presentation wil provide you the latest trends (up to March 2013) on both Global and Asia Pacific OTC markets.
This presentation is in English and Mandarine.
This document provides a global perspective on the evolving biosimilars landscape and market. It finds that after slow initial growth, the biosimilars market is poised for accelerated expansion between 2015-2020 as major biologics lose patent protection, US legislation establishes a regulatory pathway, and payers increase adoption to control costs. The market could reach $1.9-2.6 billion by 2015, up from $378 million currently, with the largest opportunities in oncology, diabetes, and rheumatoid arthritis. Key drivers include cost pressures on healthcare systems and the availability of lower-cost biosimilar alternatives to expensive biologic drugs. However, significant barriers remain due to varying regulations worldwide and resistance from biologics manufacturers.
The document summarizes the changing landscape of the top 10 pharmaceutical companies from 2002 to 2012. It notes that while the companies have remained largely the same, there has been some shuffling between positions. It also discusses how the companies have diversified their business models through mergers and acquisitions, but this has failed to increase their collective market share. The rise of Teva into the top 10 reflects a greater emphasis on generics. Overall, the top companies face challenges in innovating new blockbuster drugs and achieving growth.
The top 20 multinational pharmaceutical companies in Asia will see an average of $950 million in sales become at risk in the next 5 years due to the loss of exclusivity of their top brands. How can MNCs survive and thrive in this increasingly genericized era?
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
A joint effort undertaken by IMS Consulting Group and the Organization of Pharmaceutical Producers of India (OPPI), this white paper offers a glimpse into the findings of a survey with key management personnel in India’s pharmaceutical market about Sales Force structures within the context of changing sales models in the Indian pharma industry.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Opportunities and Challenges for HTA in Asia-Pacific (Part 2)
1. 1
Opportunities and Challenges for HTA in Asia-Pacific
Part 2 of 2 (If you missed part 1, you can also find it on SlideShare.)
A roundtable interview.
AUDIO INTERVIEW!
Turn on your speakers.
2. Opportunities and Challenges for HTA in Asia-Pacific
IMS Experts:
Mandy Chui, Practice Leader, Pricing and Market Access, APJ
Jonathan Tierce, GM, Health Economics & Outcomes Research
Guest Speakers:
Dr. Annie Chicoye, Associate Professor, ESSEC Santé Business
School France - Singapore
Dr. Abdulkadir Keskinaslan, Market Pricing Director, APAC,
Novartis Pharma AG Basel, Switzerland
Length: ~9 minutes
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
3. 3
So what can Asia-Pac learn from Europe in terms of HTA?
AC: I think the key takeaway from the experience in Europe
is that the role of HTA in the decision process may vary from
one country to another, but it has to be clear to all
stakeholders and it has to be based on appropriate data and
expertise. I can see there is clearly an opportunity in Asia-
Pacific’s emerging markets to avoid the painful process we
have been through in Europe, where it took a long decade
before HTA was really introduced and became one, but not
the only one, of the major components of the health
expenditure regulation process.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
4. 4
Thanks, Annie. And now, I think Abdulkadir can
enlighten us on some other innovative solutions that
may come out from some of the emerging countries and
in some time to come, European countries might learn
from what is going on in Asia.
AK: Thank you Jon. Yes, we having been using some
innovative partnering or contracting approaches, which we
sometimes call “pricing schemes,” to create value in Asia’s
emerging markets. In a nutshell, health care strategy is all
about how you spend your money, not how much money you
spend. What we have seen is that some countries are more
efficient than others at spending their money.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
5. 5
What do you mean by that?
AK: Well for example, the UK has proven to be five times
more productive than he US at managing Type II Diabetes.
Also I should add that we should not forget that the ultimate
goal of these contracting arrangements, these “deals,” made
by manufacturers of drugs and payer-decision maker should
be improving the value of the drug.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
6. 6
So what kinds of arrangements are there?
AK: I group them into innovative “pricing schemes” and
“market access schemes”. But we can also further group
innovative pricing schemes into “financial outcomes-based”
and “risk-based” models. The financial models are very easy
to interpret. For each patient segment, you define a price or a
reimbursement such that you progressively discount your
product as its use expands.
For outcomes-based models there are a few examples, still
tough to find in Asia, but from experiences in the UK and the
US, where reimbursement is based on the outcomes delivered
and if it isn’t delivered, the manufacturer provides a rebate.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
7. 7
And the risk-based pricing models? How do they work?
AK: Risk-based pricing models are extensively done in
Australia where you put your patient segments or indications
into different risk segments, and for each patient segment the
products are based on the relative cost-effectiveness ratio. If
it justifies the price then your ultimate price is the weighted
average price in terms of population across the different
indications.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
8. 8
These are all categorised under the Innovative Pricing
Scheme idea, but does that work in markets where the
consumers are the decision makers?
AK: That’s a good question. In these types of markets we
typically see “willingness to pay” pricing models and
“affordability based” pricing models.
How do these work?
AK: Basically on the willingness-to-pay concept, you provide
incremental discounts based on patients’ compliance. To
enhance the value of the program, you can give an upfront
discount or you can provide additional services, free
diagnostic tests if necessary, depending on the disease.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
9. 9
I see. And the Affordability model?
AK: Here you try to address the patients’ ability to pay and
you try to charge accordingly. When there is no ability to
pay, you try to provide access to patients. In the end
companies try to match their investment with growing
insurance schemes as well as some commitments from
governments.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
10. 10
Can you give us some examples of countries where this
is working?
AK: In China, we know that high price products are identified
for face-to-face negotiations. That is a different way to
negotiate prices as we looked into how things were happening
in the past. Korea, Taiwan and partially Thailand are working
on developing guidelines on how to assess this. And then in
the Philippines and Indonesia, there are a lot of differential
pricing projects also in line with the development of insurance
schemes. They are covering partially the lowest income level
of the population or some of the insurance schemes are for
governmental workers.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
11. 11
What are some of the measures that Novartis is taking?
AK: Well, in the Philippines there are a lot of examples of
patient access schemes. Novartis also has a programme, we
call it KAAGAPAY, where we try to bring disease management
programs and other benefits to the patients who enrol into
this programme. And then the Glivec® International Patient
Assistance Program, or GIPAP, is a well-known example of an
affordability based model in Asia-Pacific (and most countries
are aware of this) where a third-party assesses patients’
ability to pay and there support is provided to the patient.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
12. 12
So, do different schemes work better in certain
countries?
AK: Absolutely. For example, we have a pilot in India. Here,
for an expensive per-unit product we have provided different
options to the patient together with the physician to decide
what would be best for them. So, this could be either an
incremental discount, assigned on bonuses, but after all if the
patient needs more therapy, more vials, one option could be
a fixed discounted price, the other option could be after the
initial first three injections we have identified a fixed price
that if patient pays that then patient can claim up to nine
vials, or as many as are needed as time progresses.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
13. 13
These schemes seem highly flexible.
AK: Yes that is the idea. We are also piloting for the first time
capping a price for a self-pay, because we usually have these
kinds of agreements in the UK. We are testing whether we
can just charge a patient a certain amount and then for the
next two years the patient is free to claim as much as is
needed aligning with their physician. So based on the disease
type and the progression, physicians may choose from these
options.
Thanks Abdulkadir. It certainly seems that there are
numerous opportunities for innovative partnering and
program offerings in emerging markets. I’m sure we
will hear of more as this region develops.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
14. 14
Mandy and Annie, do you have anything to add to the
points Abdulkadir has raised? Mandy?
MC: Thank you Jon. This has been an interesting discussion, and I
would end by repeating your point earlier that we have people who
are very interested to bring HTA into Asian markets. I think Asia will
be in a good position now to learn from our European colleagues.
Hopefully, here in the Asia-Pac region, we have the potential to leap-
frog over some of the developmental history of Europe and adopt
“best practices” in HTA. Also, I am fascinated and encouraged by
these innovative, multi-stakeholder, risk-sharing arrangements. By
sharing responsibility for developing health care arrangements in the
region, we can all benefit.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
15. 15
Thank you Mandy. Annie, your final thoughts?
AC: Yes I agree with Mandy. It is time to adopt HTA here in
the Asia-Pacific region, but as I mentioned earlier, HTA would
be one component, albeit a major one, of the health
expenditure regulation process. However, we should also be
looking at some of the innovative pricing models that
Abdulkadir has been describing.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
16. 16
Thank you too Annie. Abdulkadir, your final thoughts?
AK: Yes Jon. I would say that this is an exciting time in the
region where we can learn from Europe and adapt models to
suit the rapidly developing Asia-Pacific environment.
OK, well my thanks go to our three panellists today:
Mandy Chui, Annie Chicoye and Abdulkadir Keskinasian.
And thank you, audience, for your attention.
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Know more on IMS Health, click here
17. 17
Thank you for listening!
If you missed part 1, it is also available on SlideShare!
• To download an MP3 of this interview, click here.
• To download the PDF transcript, click here.
• Questions? Comments?
− Fill out the form at the bottom of this slide, or
− Visit www.imshealth.com or email info.sg@sg.imshealth.com.